1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BioSyntech, Inc.

BioSyntech, Inc.

BSYI
BioSyntech, Inc.US flagOther OTC
0.00
USD
- -
- -
229,033.00Market Cap
BioSyntech, Inc.
BSYI
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
TTM
FRC
0.01
- -
- -
0.01
0.01
0.01
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.37
-0.23
-0.17
-0.16
-0.12
-0.11
-0.14
-0.17
-0.09
-0.1
-0.13
-0.12
Basic EPS, GAAP
-0.14
-0.08
-0.19
-0.16
-0.8
-0.08
-0.11
-0.16
-0.08
-0.09
-0.1
-0.07
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.16
0.39
0.19
0.04
-0.09
-0.02
-0.15
-0.88
-0.47
-0.56
-0.7
-0.74
Book Value per Share
-0.04
0.51
0.26
0.13
0.01
0.07
-0.05
0.21
0.11
0.01
-0.07
-0.13
Tangible Book Value per Share
11
14
29
29
29
30
36
41
94
95
96
104
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-5,250.55
-257,856,456.61
-4,377.91
-1,712.22
-2,077.76
-1,287.34
-2,685.24
-10,349.02
-3,423.19
-3,362.72
-27,056.25
-7,026.71
Operating Margin (%)
- -
- -
- -
- -
1
- -
1
1
- -
- -
- -
- -
Depreciation Expense
-4
-3
-5
-5
-4
-3
-5
-7
-8
-9
-13
-13
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-5,295.78
-223,559,669.22
-3,474.1
-1,632.33
-2,096.37
-1,447.38
-2,888.94
-11,145.52
-3,332.4
-3,383.82
-31,739.11
-6,376.72
Profit Margin (%)
-1
7
5
1
- -
2
-3
7
11
2
-7
-14
Working Capital
1
1
- -
- -
3
4
2
2
3
3
2
1
LT Debt
- -
7
8
4
- -
2
-2
9
11
2
-7
-14
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-90.73
-136.18
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'10
Sep'10
Dec'10
ST Debt
11
13
16
LT Borrowings
2
2
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
105
105
115
Market Capitalization
12
11
12

Working Capital

FRC

•

in mil. unless spec.
Jun'10
Sep'10
Dec'10
Total Current Assets
3
3
4
Cash, Cash Equivalents & STI
2
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
12
16
17
Payables & Accruals
1
2
1
ST Debt
11
13
16
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-265.79%
-265.25%
-502.14%
Free Cash Flow
83.62%
32.9%
15.29%
Net Income, GAAP
15.26%
31%
39.59%
Sales/Revenue/Turnover
995,788.36%
26.54%
-85.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
-0.02
-0.02
-0.02
- -
-0.1
2009
-0.02
-0.03
-0.05
- -
-0.13
2010
-0.03
-0.03
-0.03
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
Similar Companies
AnGes, Inc. (AMGXF)
BrightPath Biotherapeutics Co., Ltd. (4594.T)
Nordic Nanovector ASA (NANOV.OL)
BioSenic S.A. (0R55.L)
Lixte Biotechnology Holdings, Inc. (LIXT)
Forma Therapeutics Holdings, Inc. (FMTX)
Business
BioSyntech, Inc. is a biotechnology company specializing in the development, manufacture, and commercialization of medical diagnostic products and services. It offers a range of rapid diagnostic tests, including immunoassay and molecular diagnostic systems, test kits for infectious diseases, cancer biomarkers, and veterinary diagnostics. The company serves clinical laboratories, hospitals, veterinary clinics, and research institutions, primarily operating in North America and select international markets. Founded in 1998, BioSyntech is headquartered in Quebec, Canada. The company’s core product offerings include rapid immunoassay analyzers and test kits under proprietary brands that facilitate point-of-care testing and laboratory diagnostics; molecular diagnostic platforms for pathogen detection; and veterinary diagnostic products targeting animal health management. BioSyntech also provides related consumables and reagents. These products enable healthcare providers and veterinarians to perform accurate, timely diagnostic testing to improve patient and animal care outcomes. In the last two years, BioSyntech has focused on expanding its product pipeline and entering strategic partnerships to enhance its technological capabilities and market reach. Notably, it has launched new diagnostic assays for emerging infectious diseases and strengthened alliances with healthcare providers to broaden adoption of its point-of-care diagnostic platforms. The company continues to invest in research and development for precision diagnostics, while operationally optimizing manufacturing and supply chain processes to support growth. BioSyntech operates within the biotechnology and healthcare diagnostics industry, targeting clinical, veterinary, and research markets. It leverages subsidiaries to cover multiple geographic regions, ensuring distribution and localized service. The company’s commitment to innovation, quality manufacturing, and strategic collaboration positions it for sustained expansion in the competitive diagnostics sector.